Efficacy and safety of rituximab in the treatment of refractory pemfigus vulgaris

Creative Commons License

TEMEL A. B., Akman-Karakas A., Ergun E., Ozkesici B., Ugurlu N., NAZLIM B., ...Daha Fazla

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.49, sa.2, ss.117-124, 2015 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 49 Sayı: 2
  • Basım Tarihi: 2015
  • Doi Numarası: 10.4274/turkderm.86402
  • Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.117-124
  • Anahtar Kelimeler: Rituximab, pemphigus, treatment, PEMPHIGUS, THERAPY, DISORDERS, DEPLETION, DISEASES
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background and Design: Pemphigus vulgaris (PV) is a severe, chronic, potentially life-threatening autoimmune blistering disease that affects the skin and mucous membranes, associated with the loss of cell-cell adhesion and blister formation. Systemic steroids in combination with immunosuppressive agents are the mainstay of therapy in pemphigus. Rituximab, a chimeric monoclonal anti-CD20 antibody, has been tried increasingly for the treatment of PV.